Trial Profile

A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nipocalimab (Primary) ; DTaP vaccine; Pneumococcal vaccine
Indications Autoimmune haemolytic anaemia; Chronic inflammatory demyelinating polyradiculoneuropathy; Haemolytic disease of newborn; Myasthenia gravis; Myositis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
Focus Pharmacodynamics
Sponsors Janssen Research & Development

Most Recent Events

11 Oct 2023 Status changed from active, no longer recruiting to completed.
27 Jun 2023 Planned End Date changed from 9 Oct 2023 to 1 Oct 2023.
27 Jun 2023 Planned primary completion date changed from 28 Aug 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com